SCHEMBL2905511

SCHEMBL2905511

CNS(=O)(=O)c1ccc(B(O)O)c(C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.50
GAA P10253 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.47
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA3 P07451 2/20 0.44
CA4 P22748 2/20 0.44
CA6 P23280 2/20 0.44
CA5A P35218 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA13 Q8N1Q1 2/20 0.44
CA14 Q9ULX7 2/20 0.44
CA5B Q9Y2D0 2/20 0.44
TAS2R14 Q9NYV8 1/20 0.44
HTT P42858 1/20 0.43
ALDH1A1 P00352 2/20 0.42
VCAM1 P19320 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29953706 1.00 LMNA (0.56) LMNASMN1; SMN2GAAL3MBTL1CA12
SCHEMBL29958209 0.81 ALDH1A1 (0.47) GAAALDH1A1KDM4E
SCHEMBL16600609 0.81 ALDH1A1 (0.47) GAAALDH1A1KDM4E
SCHEMBL29956502 0.81 ALDH1A1 (0.54) LMNASMN1; SMN2CA1CA2CA9
SCHEMBL16195782 0.81 ALDH1A1 (0.54) LMNASMN1; SMN2CA1CA2CA9
SCHEMBL2634586 0.79 ENPP2 (0.53) LMNASMN1; SMN2ALDH1A1PKM
SCHEMBL16195567 0.79 ALDH1A1 (0.61) LMNASMN1; SMN2GAAALDH1A1MEN1
SCHEMBL29952763 0.79 CA12 (0.51) LMNAGAACA12CA1CA2
SCHEMBL29956105 0.79 ALDH1A1 (0.61) LMNASMN1; SMN2GAAALDH1A1MEN1
SCHEMBL10154281 0.79 LMNA (0.71) LMNASMN1; SMN2GAAL3MBTL1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834521-B2 Choline kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2017-12-05 US disclosed
EP-3012250-B1 ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2017-11-08 EP disclosed
US-9522145-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-12-20 US disclosed
US-20160237044-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-18 US disclosed
EP-3049406-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES AND USE THEREOF TO TREAT THROMBOTIC/THROMBOEMBOLIC DISEASES Bayer Pharma Aktiengesellschaft (DE) 2016-08-03 EP disclosed
EP-3012250-A1 ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2016-04-27 EP disclosed
US-20160024024-A1 Novel Choline Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. 2016-01-28 US disclosed
EP-2968358-A1 NOVEL CHOLINE KINASE INHIBITORS ARIAD Pharmaceuticals, Inc. (US) 2016-01-20 EP disclosed
EP-2578571-B1 Isoquinoline modulators of ATP-binding cassette transporters VERTEX PHARMA (US) 2015-09-16 EP disclosed
US-20150190390-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2015-07-09 US disclosed
US-20140206689-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-24 US disclosed
EP-2738172-A1 New bicyclic compounds as crac channel modulators Almirall, S.A. (ES) 2014-06-04 EP disclosed
US-8722704-B2 Modulators of ATP-binding cassette-transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-05-13 US disclosed
US-20130296364-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-07 US disclosed
EP-2217572-B1 ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2013-11-06 EP disclosed
US-8507524-B2 Modulators of ATP-binding cassette-transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-13 US disclosed
EP-2578571-A1 Isoquinoline modulators of ATP-binding cassette transporters Vertex Pharmaceuticals Incorporated (US) 2013-04-10 EP disclosed
EP-2217572-A1 ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2010-08-18 EP disclosed
US-20090143381-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2009-06-04 US disclosed
WO-2009064959-A1 ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024024-A1 Novel Choline Kinase Inhibitors CHKA, CHKB, CEPT1 LMNA 3535/4885SMN1; SMN2 2555/4885GAA 1368/4885
US-20150190390-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 LMNA 3795/4885SMN1; SMN2 4812/4885GAA 419/4885
US-20130296364-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS CFTR, ABCB1, ABCC2 LMNA 3826/4885SMN1; SMN2 4808/4885GAA 387/4885
US-20160237044-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES PAH, AADAT, TTR LMNA 2032/4885SMN1; SMN2 2147/4885GAA 1280/4885
US-20090143381-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS CFTR, ABCB1, ABCC2 LMNA 3826/4885SMN1; SMN2 4808/4885GAA 387/4885
US-20140206689-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 LMNA 3535/4885SMN1; SMN2 4779/4885GAA 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.